Traduction de «programs and initiatives to further » (Néerlandais → Français) :

As part of the measures, NPC will enhance many of its ongoing commitments to all employees and will add additional programs and initiatives to further strengthen its commitment to a diverse and inclusive environment.
Une partie de ces mesures consistera pour NPC à améliorer plusieurs des engagements qu’elle a pris envers ses employés et ajoutera des programmes et des projets à ceux qui existent déjà pour renforcer encore un environnement favorisant la diversité et l’intégration.

Further, our program GIPAP is one of the most far-reaching patient assistance programs ever implemented on a global scale for our anticancer product Gleevec ® /Glivec ® .
En outre, avec notre campagne GIPAP en faveur de Gleevec ® /Glivec ® , nous sommes à l’origine de l’un des programmes d’assistance les plus généreux jamais mis sur pied à l’échelle mondiale.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Project/ Potential indication/ Planned Current News update Compound Disease area submissions Phase AG0178 Major depressive disorder 2012 III - Sublingual Phase III program initiated May 2010
Syndrome de l’X fragile 2012 II - Début d’une étude pivot chez les adultes au T4 2010 AG0178 Maladie dépressive grave 2012 III - Programme de phase III pour administration sublinguale

Planned to initiate a Phase III clinical development program in chronic coronary heart disease in Q1 2011
Début d’un programme de développement clinique de phase III dans la maladie coronarienne chronique prévu

Fragile X syndrome 2012 II AG0178 Major depressive disorder 2012 III - Sublingual Phase III program initiated May 2010
AG0178 Maladie dépressive grave 2012 III - Programme de phase III pour administration sublinguale

R&D investments (+1.0 percentage points) were lower as productivity initiatives more than offset investments in development programs for biosimilars as well as other differentiated generics, including oncology injectables and respiratory products.
Les investissements en R&D (+1,0 point de pourcentage) ont diminué car les gains de productivité ont plus que compensé les investissements dans les programmes de développement de biosimilaires ainsi que d’autres génériques différenciés, comprenant les injectables en oncologie et les produits contre les maladies des voies respiratoires.

De HGR zal in 2012 dan ook trachten actief te participeren aan één of meer samenwerkingsprojecten binnen EuSANH, hetzij onder vorm van bilaterale samenwerking, hetzij onder vorm van een participatie in een breder internationaal kader zoals Joint Actions, Joint Programming Initiatives, ….
Le CSS tentera dès lors de tout mettre en œuvre en 2012 pour participer activement à un ou plusieurs projets de coopération dans le cadre de EuSANH, soit sous forme de collaboration bilatérale, soit sous forme de participation dans un cadre international plus large comme les Joint Actions, Joint Programming Initiatives, ….

“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis. “We are proud to be a part of this innovative effort to support a healthier world”.
“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis.

Initial data from the Phase III program with over 4,200 patients in 30 countries suggest a good efficacy/safety profile.
Les premiers résultats fournis par un programme de phase III impliquant plus de 4 200 patients dans 30 pays indiquent un bon profil efficacité/innocuité.